Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Seres Therapeutics, Inc. - Common Stock (NQ:MCRB)

0.6762 -0.0239 (-3.41%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Seres Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Seres Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics to Host Second Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2021
From Seres Therapeutics, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For July 23, 2021
Upgrades Craig-Hallum upgraded the previous rating for Lindblad Expeditions Holdings Inc (NAS... 
Via Benzinga
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results.... 
Via Benzinga
Exposures Product Safety
Analyst Ratings For Seres Therapeutics
Within the last quarter, Seres Therapeutics (NASDAQ:MCRB)... 
Via Benzinga
10 Biggest Price Target Changes For Friday
Keybanc raised the price target on Twitter, Inc. (NYSE: TWTR) from $77 to $81. Twitter shares rose 6.4% to $74.00 in pre-market trading. Baird boosted the price target for... 
Via Benzinga
61 Biggest Movers From Yesterday
Gainers ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) shares jumped 138.2% to close at $13.22 on Thursday after the company announced new results from its TATX-03 PolyTope Therapy... 
Via Benzinga
Mid-Afternoon Market Update: Dow Rises Over 50 Points; ImmunoPrecise Antibodies Shares Spike Higher
Toward the end of trading Thursday, the Dow traded up 0.16% to 34,853.89 while the NASDAQ rose 0.38% to 14,687.85. The S&P also rose, gaining 0.20% to 4,367.55. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
38 Stocks Moving In Thursday's Mid-Day Session
Gainers ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) shares climbed 129.7% to $12.75 after the company announced new results from its TATX-03 PolyTope Therapy, demonstrating... 
Via Benzinga
Stocks Flat as Nasdaq Tries For 3 Straight
A surprise jump in jobless claims is weighing on investor sentiment midday. The Dow Jones Industrial Average is down 34 points, while the S&P 500 Index is trading near breakeven. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Mid-Day Market Update: Crude Oil Up 1.5%; Seres Therapeutics Shares Plunge
Midway through trading Thursday, the Dow traded down 0.08% to 34,768.64 while the NASDAQ rose 0.10% to 14,646.39. The S&P also fell, dropping 0.02% to 4,357.70. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers NRX Pharmaceuticals (NASDAQ:NRXP) stock increased by 53.01% to $15.47 during Thursday's regular session. As of 12:30 EST, this security is trading at a volume... 
Via Benzinga
Why Seres Therapeutics Stock Is Crashing Today
The company reported disappointing results from a phase 2b clinical study. 
Via The Motley Fool
Mid-Morning Market Update: Markets Mostly Lower; AT&T Beats Q2 Estimates
Following the market opening Thursday, the Dow traded down 0.24% to 34,715.42 while the NASDAQ rose 0.13% to 14,651.19. The S&P also fell, dropping 0.08% to 4,355.29. The U.S... 
Via Benzinga
Topics Stocks
Exposures US Equities
The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, AbSci IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21) Biohaven Pharmaceutical... 
Via Benzinga
Exposures Product Safety
Seres Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2b Study of SER-287 to Treat Mild-to-Moderate Ulcerative Colitis
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Stock Plunges As Ulcerative Colitis Candidate Disappoints In Mid-Stage Study
Seres Therapeutics Inc (NASDAQ: MCRB) has announced topline results from the Phase 2b ECO-RESET study evaluating SER-287 in patients with mild-to-moderate ulcerative colitis... 
Via Benzinga
Seres Therapeutics Announces Topline Results for SER-287 Phase 2b Study in Mild-to-Moderate Ulcerative Colitis
From Seres Therapeutics, Inc.
Via Business Wire
Nestlé Bets $525M On Seres Therapeutics Microbiome Drug For Infectious Diseases
Seres Therapeutics Inc (NASDAQ: MCRB) has inked a $525-million deal with Nestlé Health Science to commercialize SER-109 if it can win FDA approval. SER-109 is an... 
Via Benzinga
Exposures Product Safety
Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics to Present at JMP Securities Life Sciences Conference
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics to Host Virtual Investor Event on June 21, 2021
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Presents Research from its Early-Stage Microbiome Therapeutic Oncology Programs at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Gets FDA Green Signal to Start SER-155 Human Trials
The FDA has signed off Seres Therapeutics Inc's (NASDAQ: MCRB) Investigational New Drug (IND) application for SER-155 to initiate Phase 1 trial. SER-155 is a... 
Via Benzinga
Exposures Product Safety
Seres Therapeutics Announces FDA Clearance of IND for SER-155, an Investigational Microbiome Therapeutic for the Prevention of Antibiotic-Resistant Bacterial Infections and Graft-versus-Host Disease (GvHD)
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics to Present at Upcoming Virtual Investor Conferences
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Presents Data Across its Broad Microbiome Pipeline Including New 24-Week Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at Digestive Disease Week 2021
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Announces David Arkowitz to Join as Executive Vice President, Chief Financial Officer and Head of Business Development
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics to Present Clinical Research on the Microbiome’s Impact on Allogeneic Hematopoietic Stem Cell Transplantation and Cancer Immunotherapy at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics to Present at RBC Capital Markets 2021 Global Healthcare Conference
From Seres Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.